Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Harbin Pharmaceutical Group Co EV-to-EBITDA?
Harbin Pharmaceutical Group CoSHSE:600664 +3.37%56 EV-to-EBITDA is 22.44 as of Sep. 16, 2026, which is 91% above its 10-year median of 11.74. GuruFocus rates SHSE:600664 with a GF Score™ of 56/100 and a GF Value™ of ¥3.67 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 744 Drug Manufacturers companies, Harbin Pharmaceutical Group Co ranks worse than 62.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Harbin Pharmaceutical Group Co's enterprise value is ¥17,244 Mil.
Harbin Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥769 Mil. Therefore, Harbin Pharmaceutical Group Co's EV-to-EBITDA for today is 22.44.
The historical rank and industry rank for Harbin Pharmaceutical Group Co's EV-to-EBITDA or its related term are showing as below:
SHSE:600664'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -143.05 Med: 11.74 Max: 357.26
Current: 16.39
During the past 13 years, the highest EV-to-EBITDA of Harbin Pharmaceutical Group Co was 357.26. The lowest was -143.05. And the median was 11.74.
SHSE:600664's EV-to-EBITDA is ranked worse than 62.23% of 744
companies
in the Drug Manufacturers industry
Industry Median: 12.245
vs SHSE:600664: 16.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Harbin Pharmaceutical Group Co (SHSE:600664) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Harbin Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Harbin Pharmaceutical Group Co's share price for today is ¥7.36.
Harbin Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.203.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harbin Pharmaceutical Group Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Harbin Pharmaceutical Group Co's EV-to-EBITDA falls into.
Harbin Pharmaceutical Group Co's current Enterprise Value is ¥17,244 Mil.
Harbin Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥769 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harbin Pharmaceutical Group Co (SHSE:600664) has a EV-to-EBITDA of 22.44 as of Sep. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Harbin Pharmaceutical Group Co. This is 91% above median its historical median of 11.74. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #463 out of 744 companies in the Drug Manufacturers industry, placing it in the top 62.2%.
Is Harbin Pharmaceutical Group Co's EV-to-EBITDA too high?
Harbin Pharmaceutical Group Co's current EV-to-EBITDA of 22.44 is 91% above median its 10-year median of 11.74. The Drug Manufacturers industry median EV-to-EBITDA is 12.25. Harbin Pharmaceutical Group Co's value of 22.44 is 83.3% above this industry median. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #463 out of 744 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #463 out of 744 companies for EV-to-EBITDA. This places Harbin Pharmaceutical Group Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.25. Harbin Pharmaceutical Group Co's value of 22.44 is 83.3% above this benchmark. While the company's 10-year median is 11.74 vs. the industry median of 12.25, Harbin Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.25, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harbin Pharmaceutical Group Co's current EV-to-EBITDA of 22.44 is 83.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Harbin Pharmaceutical Group Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current EV-to-EBITDA is 22.44, which is 91% above median its own 10-year median of 11.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.67, compared to a current price of ¥7.36 — trading 100.5% above its estimated fair value. The current EV-to-EBITDA is 22.44, which is 91% above median its 10-year median of 11.74 and 83.3% above the Drug Manufacturers industry median of 12.25. Harbin Pharmaceutical Group Co's overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current EV-to-EBITDA is 22.44 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥7.36 is trading 100.5% above its estimated GF Value™ of ¥3.67.
GuruFocus considers Harbin Pharmaceutical Group Co to be Significantly Overvalued.
Key valuation signals for SHSE:600664:
EV-to-EBITDA: 22.44 (91% above median its 10-year median of 11.74)
GF Value™: ¥3.67 vs. price of ¥7.36 (100.5% above fair value)
Industry Position: 83.3% above the Drug Manufacturers median (#463 of 744)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
56GF Score
Get the complete analysis for SHSE:600664
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 
